Hedgehog signaling plays a critical role during development and tumorigenesis. While much mechanistic insight has come from pathway investigations in the fruit fly, recent studies suggest a distinct mammalian strategy for signaling from Smoothened to Gli through the novel protein Suppressor of Fused that may have therapeutic implications.
The challenge of developing therapeutic inhibitors and activators of major signaling pathways comes when the targets at which one aims keep moving. This is the case with the components of the hedgehog (Hh) signaling pathway in mammals. Hh plays a crucial role in development and tumorigenesis in metazoan organisms and promotes proliferation, inhibits differentiation, and controls migration of stem cells in the body. Inappropriate Hh signaling results in a panoply of developmental defects and cancers and is implicated in the induction, maintenance, and/or metastasis of up to 25% of human tumors (Lum and Beachy, 2004) . Intense focus has been centered around how the Hh signal transduced by the serpentine receptor Smoothened (Smo) is interpreted by the Gli/Cubitus interruptus (Ci) zinc finger family of transcription factors, as this interpretation determines the magnitude and quality of the resultant Hh-dependent target gene induction. The elegant genetic and cell biological tools in Drosophila have provided the logic of the pathway and identified many key components. However, recent mammalian studies, including two in this issue of Developmental Cell, reveal critical differences that have implications for therapeutic targeting.
In both the invertebrate and vertebrate pathways, Hh ligand binds and inhibits the Patched receptor, allowing Smo to tip the balance of activity of the Gli/Ci proteins from repression to activation (Figure 1 ). Smo does this in a graded fashion in two ways. First, Smo blocks protein kinase-dependent Gli3/Ci repressor formation that occurs through the cleavage of full-length Gli3/Ci into a smaller transcriptional repressor. Blocking this cleavage allows low-level expression of derepressed Hh target genes. Second, for higher levels of pathway activity, Smo also enhances the full-length, activator forms of Gli/Ci. In mammals the main activators are Gli1 and Gli2.
Surprising recent data indicates that mammals have adopted distinct strategies to control Smo signal transmission to Gli. In flies, the atypical kinesin protein costal2 (Cos2) is a key interpreter of the signal from Smo. It does so by scaffolding Ci on vesicles with cleavagepromoting kinases, thus allowing Ci phosphorylation and subsequent Ci repressor formation (Zhang et al., 2005) . With the addition of Hh, Smo binds and sequesters Cos2 away from the kinases, preventing efficient Ci repressor formation. Moreover, Cos2 appears to play an additional role in stimulating activator forms. This is done by scaffolding the kinase Fused, which acts positively to increase the transcriptional activity of fulllength Ci (Kalderon, 2004) .
By contrast, Varjosalo and colleagues in this issue show that in mammals Cos2 orthologs KIF7 and KIF27 are not required to regulate Sonic hedgehog (Shh) signaling (Varjosalo et al., 2006) . siRNAs that reduce KIF levels in a variety of cells fail to alter Gli transcription, suggesting that they no longer serve a function or that other mammalian kinases can function in their place. While this study was done in vitro and may not reflect signaling in the animal, the authors further show that Smo signaling is also different both in vitro and in trans- So what takes the place of Cos2? Increasing data suggest that the primary cilium serve the analogous function. Primary cilia are small microtubule-based organelles that use the transport of membrane bound cargo for signal processing and cellular movement (Corbit et al., 2005; Haycraft et al., 2005) . Extensive forward genetic screens in mice have uncovered a set of mutants resembling Shh mutants (Huangfu and Anderson, 2006) , but which contain mutations in components of the primary cilium. Each mutant has abnormal cilia and an impaired ability to cleave Gli3 into a repressor, and fail to stimulate Gli2 into an activator, similar to the Drosophila cos2 phenotype. Further support for a direct role of the organelle in processing comes from the colocalization of all three Gli proteins and Smo with acetylated tubulin, a cilium marker (Corbit et al., 2005; Haycraft et al., 2005) . More experimentation is required to understand how this small membrane specialization, either directly or indirectly, controls kinase activity and Gli processing.
Another big surprise is the key role played by the novel protein Suppressor of Fused (Sufu). Sufu was originally identified genetically in Drosophila by its ability to suppress overactive fused mutations, but is not itself required for pathway activity. This has subjected Sufu to an also-ran role in the pathway for many years. However, the reports in this issue (Svard et al., 2006; Varjosalo et al., 2006) and elsewhere (Cooper et al., 2005) suggest that a key negative regulatory role has been assumed by Sufu. Sufu null mouse mutants not only fail to repress the pathway, but have similar phenotypes as the other key negative regulator acting upstream, patched1. Moreover, Sufu null MEFs and wild-type cells treated with Sufu siRNAs display maximal pathway activation, supporting a central role in pathway repression (Svard et al., 2006; Varjosalo et al., 2006) . Interestingly, in one study the skin phenotype of Sufu +/2 mice was more severe than that of ptch +/2 mice, as the former spontaneously developed hair follicle tumors (Svard et al., 2006) . The result, not seen in the other studies, could suggest a true divergence in signaling between patched1 and Sufu, or could be due to allele or genetic background differences. The fact that Sufu plays a critical negative regulatory role in the pathway is accompanied by a dearth of information about how Sufu functions to help transmit Smo signals to Gli. While the entire Sufu protein is highly conserved, the lack of recognizable functional domains makes predicting how and where it acts difficult. Numerous previous reports have demonstrated that Sufu binds and sequesters Gli1 in the cytoplasm, and one study shows it works as a transcriptional corepressor in the nucleus (Huangfu and Anderson, 2006) . Recent data localizing endogenous Sufu in the primary cilium with Smo and Gli proteins supports the provocative hypothesis that Sufu may also have a role with Smo in Gli processing in addition to its purported role in the nucleus (Haycraft et al., 2005) . Evidence from this issue argues against a subcellular localization role, as transfected Gli1 remains cytoplasmic in Sufu mutant cells (Svard et al., 2006) . Future studies examining the phosphorylation, processing, and activity of the Gli proteins in Sufu mutants may help better pinpoint Sufu activities.
The emerging mammalian variations of how Smo signals to Gli are likely to provide a host of new targets for therapy. Already, Sufu mimetics and antagonists of the components of the primary cilium appear to be two recent additions. From novel screens to identify pathway genes, a number of apparently mammalian-specific
A Role for Neurotrophins in Embryonic Stem Cell Growth
Neurotrophins act on embryonic cells through TRK receptors to inhibit apoptosis by phosphorylation of AKT. In a recent paper in Nature Biotechnology, Pyle et al. (2006) show that the presence of selected neurotrophins enables cloning of trypsinized single embryonic stem cells and potentially increases the availability and usefulness of these stem cells.
Human embryonic stem cells (hESCs) are formed from the inner cell mass (ICM) of developing blastocyst stage preimplantation embryos (Reubinoff et al., 2000; Thomson et al., 1998) . hESCs remain undifferentiated when grown in tightly packed colonies in culture with mouse embryonic fibroblasts (MEFs) (Reubinoff et al., 2000; Thomson et al., 1998) or human embryonic fibroblasts (Amit et al., 2003) and several other cell types. When overgrown in culture or in the absence of live MEFs, hESC colonies begin to differentiate, particularly at the periphery and center of the colony. While MEF-conditioned medium can be used to grow hESCs, it is difficult to maintain euploidy and survival of undifferentiated colonies. Passage of hESCs is done weekly or more often by mechanical division of the colony by using finely drawn glass needles or scalpel fragments. Trypsinization of the colonies and clonal derivation of the hESCs has also been difficult and is commonly associated with chromosomal abnormalities, high rates of cell death, and differentiation (Pera, 2004) . These technical barriers have proved a limitation on hESC studies.
Leukemia inhibiting factor (LIF) is able to maintain mouse ESCs by activation of the Jak/STAT signaling pathway in the absence of MEF feeders and facilitates their renewal, clonal derivation, and genetic manipulation. hESCs cannot be maintained by LIF, so it seems likely that alternative signaling pathway(s) are used for maintenance and growth of hESCs. A search for cytokines that would enable large-scale, high-throughput production of hESCs and their clonal derivation has been a priority for human stem cell biology.
Pyle and colleagues set out to identify factors that would promote the growth and survival of hESCs. In their new study, just published in Nature Biotechnology (Pyle et al., 2006) , they describe a role for neurotrophins in hESC maintenance and renewal. They examined microarray and SAGE data for evidence of the expression of cell surface signaling receptors of tyrosine kinases, and this analysis led to a focus on neurotrophins and their receptors. Importantly, their discovery has enabled Pyle et al. to develop a technique that improves the efficiency of clonal derivation of hESCs. This may well be a very significant development in embryonic stem cell biology.
Neurotrophins are a family of growth factors which include nerve growth factor, brain-derived nerve growth factor, and neurotrophins (NT) 3 and 4. They act through binding of their specific receptors: tropomyosin receptor kinases (TRK; consisting of TRKA, TRKB and TRKC) and p75 neurotrophin receptor (p75NGFR) (reviewed in Lu et al., [2005] ). Pyle et al. thought the TRK tyrosine kinase receptors ''might act as receptors for antiapoptotic factors'' on hESCs. The lead for this hypothesis is the need to maintain hESCs colonies at >10 cells to retain their viability during passage on MEFs or MEF-conditioned medium. Two hESC lines (HI and H9) tested showed high levels of TRKB and TRKC expression. TRKB binds BDNF and NT4, while TRKC binds NT3 (Lu et al., 2005) . Importantly, the MEF
